{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:41:01Z","timestamp":1777016461616,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Bundeswehrkrankenhaus Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Immuncheckpoint-Inhibitoren in Kombination mit konventioneller Chemotherapie haben im neoadjuvanten und perioperativen Setting des nichtkleinzelligen Lungenkarzinoms (NSCLC) zu deutlich verbesserten onkologischen Ergebnissen gef\u00fchrt und sind als Standardtherapie f\u00fcr Patienten in den UICC-Stadien IIA\u2013IIIA etabliert. Damit gewinnt die pathologische Beurteilung der therapieinduzierten Tumorregression an Bedeutung. Der Artikel gibt einen \u00dcberblick \u00fcber die aktuellen Empfehlungen zur makroskopischen Aufarbeitung, histologischen Bewertung und zum Staging von NSCLC-Resektaten nach neoadjuvanter Chemoimmuntherapie. Wesentliche Aspekte umfassen die makroskopische Aufarbeitung des Tumorbettes, die quantitative Erfassung der Tumorbettkomponenten (vitaler Tumor, Stroma\/Entz\u00fcndung, Nekrose) in 10\u202f%-Schritten sowie die Anwendung etablierter Regressionsgraduierungen (IASLC, Junker). Zudem werden Herausforderungen bei der Abgrenzung therapieinduzierter Ver\u00e4nderungen, der Bewertung von Lymphknoten und der Stadieneinteilung nach neoadjuvanter Therapie erl\u00e4utert. Die aktuelle Datenlage unterstreicht die Notwendigkeit einer standardisierten Vorgehensweise bei der pathologischen Diagnostik sowie weiterer Untersuchungen, um pr\u00e4diktive Biomarker zu identifizieren und die prognostische Aussagekraft der pathologischen Regressionsgraduierung zu verbessern.<\/jats:p>","DOI":"10.1007\/s00292-026-01544-z","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T13:37:20Z","timestamp":1771940240000},"page":"205-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update zur Regressionsgraduierung nichtkleinzelliger Lungenkarzinome","Update on the regression grading of non-small cell lung cancer"],"prefix":"10.1007","volume":"47","author":[{"given":"Felix","family":"Elsner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena-Maria","family":"L\u00f6wer-Kiem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Berezowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6549-9848","authenticated-orcid":false,"given":"Konrad","family":"Steinestel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"1544_CR1","unstructured":"Anonymous S3-Leitlinie Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. In:"},{"key":"1544_CR2","doi-asserted-by":"publisher","first-page":"S600","DOI":"10.1016\/j.jtho.2025.09.1133","volume":"20","author":"S Berezowska","year":"2025","unstructured":"Berezowska\u00a0S, Dacic\u00a0S, Weissferdt\u00a0A et\u00a0al (2025) PT1.07.01 IASLC Multidisciplinary Recommendations for Pathological Response Evaluation of Resected Lymph Nodes After Neoadjuvant Therapy in NSCLC. Journal of Thoracic Oncology 20:S600","journal-title":"Journal of Thoracic Oncology"},{"key":"1544_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00428-013-1404-6","volume":"462","author":"JL Blaauwgeers","year":"2013","unstructured":"Blaauwgeers\u00a0JL, Kappers\u00a0I, Klomp\u00a0HM et\u00a0al (2013) Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. Virchows Arch 462:547\u2013556","journal-title":"Virchows Arch"},{"key":"1544_CR4","first-page":"573","volume":"391","author":"T Cascone","year":"2024","unstructured":"Cascone\u00a0T, Spicer\u00a0JD, Provencio Pulla\u00a0M (2024) Perioperative Nivolumab in Resectable Lung Cancer Reply. N Engl J Med 391:573\u2013574","journal-title":"N Engl J Med"},{"key":"1544_CR5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell\u00a0TR, Thompson\u00a0ED, Forde\u00a0PM et\u00a0al (2018) Pathologic features of response to neoadjuvant anti-PD\u20111 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 29:1853\u20131860","journal-title":"Ann Oncol"},{"key":"1544_CR6","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.5858\/arpa.2024-0203-RA","volume":"149","author":"S Dacic","year":"2025","unstructured":"Dacic\u00a0S (2025) Neoadjuvant Therapy and Lung Cancer: Role of Pathologists. Arch Pathol Lab Med 149:e78\u2013e81","journal-title":"Arch Pathol Lab Med"},{"key":"1544_CR7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jtho.2023.07.017","volume":"18","author":"S Dacic","year":"2023","unstructured":"Dacic\u00a0S, Travis\u00a0W, Redman\u00a0M et\u00a0al (2023) International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. J\u00a0Thorac Oncol 18:1290\u20131302","journal-title":"J Thorac Oncol"},{"key":"1544_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jtho.2023.12.010","volume":"19","author":"S Dacic","year":"2024","unstructured":"Dacic\u00a0S, Travis\u00a0WD, Giltnane\u00a0JM et\u00a0al (2024) Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study. J\u00a0Thorac Oncol 19:719\u2013731","journal-title":"J Thorac Oncol"},{"key":"1544_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","volume":"30","author":"JS Deutsch","year":"2024","unstructured":"Deutsch\u00a0JS, Cimino-Mathews\u00a0A, Thompson\u00a0E et\u00a0al (2024) Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med 30:218\u2013228","journal-title":"Nat Med"},{"key":"1544_CR10","unstructured":"Deutsch JS, Scolyer RA, Burton E et\u00a0al. Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A\u00a0joint SITC and INMC effort. Annals of Oncology"},{"key":"1544_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/his.15550","volume":"87","author":"F Elsner","year":"2025","unstructured":"Elsner\u00a0F, Kumpers\u00a0C, Ott\u00a0G et\u00a0al (2025) Current practice of pathologic response assessment following chemoimmunotherapy for non-small cell lung cancer (NSCLC) in Germany: first real-world data from the multicentre Re-GraDE study. Histopathology 87:869\u2013879","journal-title":"Histopathology"},{"key":"1544_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa2502931","volume":"393","author":"PM Forde","year":"2025","unstructured":"Forde\u00a0PM, Spicer\u00a0JD, Provencio\u00a0M et\u00a0al (2025) Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. N Engl J Med 393:741\u2013752","journal-title":"N Engl J Med"},{"key":"1544_CR13","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach\u00a0JV, Harpole\u00a0D, Mitsudomi\u00a0T et\u00a0al (2023) Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med 389:1672\u20131684","journal-title":"N Engl J Med"},{"key":"1544_CR14","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1378\/chest.120.5.1584","volume":"120","author":"K Junker","year":"2001","unstructured":"Junker\u00a0K, Langner\u00a0K, Klinke\u00a0F et\u00a0al (2001) Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest 120:1584\u20131591","journal-title":"Chest"},{"key":"1544_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00292-003-0643-8","volume":"25","author":"K Junker","year":"2004","unstructured":"Junker\u00a0K, Muller\u00a0KM, Abker\u00a0S et\u00a0al (2004) Cellular changes in non-small cell lung cancer after neoadjuvant therapy. Pathologe 25:193\u2013201","journal-title":"Pathologe"},{"key":"1544_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/BF01192200","volume":"123","author":"K Junker","year":"1997","unstructured":"Junker\u00a0K, Thomas\u00a0M, Schulmann\u00a0K et\u00a0al (1997) Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J\u00a0Cancer Res Clin Oncol 123:469\u2013477","journal-title":"J Cancer Res Clin Oncol"},{"key":"1544_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1046\/j.1365-2559.1998.00453.x","volume":"33","author":"KM Kerr","year":"1998","unstructured":"Kerr\u00a0KM, Johnson\u00a0SK, King\u00a0G et\u00a0al (1998) Partial regression in primary carcinoma of the lung: does it occur? Histopathology 33:55\u201363","journal-title":"Histopathology"},{"key":"1544_CR18","volume":"2","author":"JM Lee","year":"2021","unstructured":"Lee\u00a0JM, Kim\u00a0AW, Marjanski\u00a0T et\u00a0al (2021) Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC. JTO Clin Res Rep 2:100221","journal-title":"JTO Clin Res Rep"},{"key":"1544_CR19","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41379-021-00871-1","volume":"34","author":"X Liu","year":"2021","unstructured":"Liu\u00a0X, Sun\u00a0W, Wu\u00a0J et\u00a0al (2021) Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer. Mod Pathol 34:1990\u20131998","journal-title":"Mod Pathol"},{"key":"1544_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu\u00a0S, Zhang\u00a0W, Wu\u00a0L et\u00a0al (2024) Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA 331:201\u2013211","journal-title":"JAMA"},{"key":"1544_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","volume":"7","author":"A Pataer","year":"2012","unstructured":"Pataer\u00a0A, Kalhor\u00a0N, Correa\u00a0AM et\u00a0al (2012) Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J\u00a0Thorac Oncol 7:825\u2013832","journal-title":"J Thorac Oncol"},{"key":"1544_CR22","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jtho.2021.03.029","volume":"16","author":"A Pataer","year":"2021","unstructured":"Pataer\u00a0A, Weissferdt\u00a0A, Vaporciyan\u00a0AA et\u00a0al (2021) Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. J\u00a0Thorac Oncol 16:1289\u20131297","journal-title":"J Thorac Oncol"},{"key":"1544_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.5858\/arpa.2019-0615-SA","volume":"144","author":"N Rekhtman","year":"2020","unstructured":"Rekhtman\u00a0N (2020) \u201cNapoleon Hat\u201d Sign: A Distinctive Cytologic Clue to Reactive Pneumocytes. Arch Pathol Lab Med 144:443\u2013445","journal-title":"Arch Pathol Lab Med"},{"key":"1544_CR24","volume":"3","author":"A Saqi","year":"2022","unstructured":"Saqi\u00a0A, Leslie\u00a0KO, Moreira\u00a0AL et\u00a0al (2022) Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice. JTO Clin Res Rep 3:100310","journal-title":"JTO Clin Res Rep"},{"key":"1544_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1200\/JCO.1999.17.4.1185","volume":"17","author":"M Thomas","year":"1999","unstructured":"Thomas\u00a0M, Rube\u00a0C, Semik\u00a0M et\u00a0al (1999) Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J\u00a0Clin Oncol 17:1185","journal-title":"J Clin Oncol"},{"key":"1544_CR26","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jtho.2016.03.025","volume":"11","author":"WD Travis","year":"2016","unstructured":"Travis\u00a0WD, Asamura\u00a0H, Bankier\u00a0AA et\u00a0al (2016) The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J\u00a0Thorac Oncol 11:1204\u20131223","journal-title":"J Thorac Oncol"},{"key":"1544_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","volume":"15","author":"WD Travis","year":"2020","unstructured":"Travis\u00a0WD, Dacic\u00a0S, Wistuba\u00a0I et\u00a0al (2020) IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J\u00a0Thorac Oncol 15:709\u2013740","journal-title":"J Thorac Oncol"},{"key":"1544_CR28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee\u00a0H, Liberman\u00a0M, Kato\u00a0T et\u00a0al (2023) Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med 389:491\u2013503","journal-title":"N Engl J Med"},{"key":"1544_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100353","volume":"37","author":"A Weissferdt","year":"2024","unstructured":"Weissferdt\u00a0A, Leung\u00a0CH, Lin\u00a0H et\u00a0al (2024) Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Mod Pathol 37:100353","journal-title":"Mod Pathol"},{"key":"1544_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cllc.2019.11.003","volume":"21","author":"A Weissferdt","year":"2020","unstructured":"Weissferdt\u00a0A, Pataer\u00a0A, Vaporciyan\u00a0AA et\u00a0al (2020) Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer 21:341\u2013348","journal-title":"Clin Lung Cancer"},{"key":"1544_CR31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1055\/a-2465-4830","volume":"79","author":"K Welcker","year":"2025","unstructured":"Welcker\u00a0K, Jonigk\u00a0D, Kropf-Sanchen\u00a0C et\u00a0al (2025) Neoadjuvant therapy for resectable non-small cell lung cancer. Pneumologie 79:16\u201324","journal-title":"Pneumologie"},{"key":"1544_CR32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","volume":"11","author":"H Yu","year":"2016","unstructured":"Yu\u00a0H, Boyle\u00a0TA, Zhou\u00a0C et\u00a0al (2016) PD-L1 Expression in Lung Cancer. J\u00a0Thorac Oncol 11:964\u2013975","journal-title":"J Thorac Oncol"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01544-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-026-01544-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01544-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:58:11Z","timestamp":1777013891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-026-01544-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1007\/s00292-026-01544-z","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Elsner, L.-M.\u00a0L\u00f6wer-Kiem, F.\u00a0Fuchs, S.\u00a0Berezowska und K.\u00a0Steinestel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}